What is Minerva Neurosciences, Inc's earnings per share (EPS)?

Minerva Neurosciences, Inc (NERV) reported diluted earnings per share of -$34.67 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Minerva Neurosciences, Inc (NERV) Financials

NERV

FY2025 annual

Revenue Not reported for FY2025

Net Income -$293.4M -20492.7% YoY

EPS (Diluted) -$34.67 YoY not available

Operating Cash Flow -$13.5M +30.9% YoY

Market Cap $151.8M as of Oct 10, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NERV SEC filings page.

This page shows Minerva Neurosciences, Inc (NERV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NERV FY2025 2026-10-03

The numbers describe a non-revenue business whose operating losses narrowed while a large below-operating-line item deepened balance-sheet strain.

FY2025 shows a sharp earnings-quality gap: the -$15.1M operating loss sits far above the -$293.4M net loss, pointing to a substantial below-operating-line item rather than deterioration in core operating costs alone.

The balance sheet remains structurally weak: FY2025 liabilities reached $233.8M against $98.0M of assets, leaving equity at -$140.7M. A $74.5M financing inflow increased assets, but did not restore positive net worth.

Cash use improved unevenly, from -$19.6M of operating cash flow in FY2024 to -$13.5M in FY2025, while R&D fell from $11.9M to $5.8M. That pairing suggests the smaller cash outflow partly reflects reduced development spending, not an operating revenue engine; reported liquidity equaled 73.1 months of the latest annual outflow comparison.

Financial Health Signals

Financial health score not available

Minerva Neurosciences, Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Minerva Neurosciences, Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Minerva Neurosciences, Inc reported a net loss of $293.4M while operations used $13.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

$17.5M

YoY+636.0%

QoQ+113.9%

Minerva Neurosciences, Inc reported $17.5M in net income in Q2 2026. This represents an increase of 636.0% from the same quarter a year earlier. Against the prior quarter it is up 113.9%.

EPS (Diluted)

-$0.14

QoQ+95.1%

Minerva Neurosciences, Inc earned -$0.14 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 95.1%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$24.7M

YoY+61.7%

QoQ-24.5%

5Y CAGR-19.8%

10Y CAGR-12.0%

Minerva Neurosciences, Inc held $24.7M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

48M

QoQ+2.5%

5Y CAGR+2.2%

10Y CAGR+3.2%

Minerva Neurosciences, Inc had 48M shares outstanding in Q2 2026. Against the prior quarter it is up 2.5%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

None of these metrics is reported for Q2 2026.

Capital Allocation

R&D Spending

$7.2M

YoY+453.7%

QoQ+36.8%

Minerva Neurosciences, Inc invested $7.2M in research and development in Q2 2026. This represents an increase of 453.7% from the same quarter a year earlier. Against the prior quarter it is up 36.8%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

NERV Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NERV quarterly income statement

Metric	TTM	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	N/A	N/A	$0	$0	$0	$0-100.0%	$41.2M	$0	$0	$0	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$5.8M-51.6%	$11.9M-6.3%	$12.7M-13.3%	$14.6M-54.3%	$32.0M+45.4%	$22.0M-62.1%	$58.1M+66.6%	$34.9M+15.3%	$30.3M+48.0%	$20.4M+10.3%	$18.5M-56.8%	$42.9M+5956.3%	$708K
SG&A Expenses	N/A	$9.3M-6.1%	$9.9M-4.5%	$10.4M-1.6%	$10.6M-20.6%	$13.3M-22.9%	$17.3M-2.5%	$17.7M+5.3%	$16.8M+54.3%	$10.9M+11.9%	$9.8M+28.7%	$7.6M-36.7%	$12.0M+385.0%	$2.5M
Operating Income	N/A	-$15.1M+30.9%	-$21.8M+5.5%	-$23.1M+8.4%	-$25.2M+44.4%	-$45.4M-2556.5%	$1.8M+102.4%	-$75.9M-46.7%	-$51.7M-25.6%	-$41.2M-36.4%	-$30.2M-15.6%	-$26.1M+52.4%	-$54.9M-1628.2%	-$3.2M
EBITDA	N/A	-$15.1M+30.9%	-$21.8M+5.5%	-$23.1M	N/A	N/A	$1.9M+102.5%	-$75.8M-46.7%	-$51.7M-25.6%	-$41.2M-36.4%	-$30.2M-15.6%	-$26.1M+52.4%	-$54.8M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$110K-82.0%	$614K-40.3%	$1.0M-2.2%	$1.1M-48.6%	$2.0M+3631.0%	-$58K
Income Tax	N/A	N/A	N/A	N/A	N/A	-$1.8M	N/A	-$2.3M	$0+100.0%	-$9.4M	$0	$0	N/A	N/A
Net Income	N/A	-$293.4M-20492.7%	$1.4M+104.8%	-$30.0M+6.6%	-$32.1M+35.7%	-$49.9M-2671.4%	$1.9M+102.7%	-$72.2M-43.9%	-$50.2M-59.2%	-$31.5M-1.5%	-$31.0M-14.6%	-$27.1M+52.4%	-$56.9M-1644.4%	-$3.3M
EPS (Basic)	N/A	-$34.67-18347.4%	$0.19+104.1%	-$4.61+23.3%	-$6.01+35.7%	-$9.35-18800.0%	$0.05+102.7%	-$1.85	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$34.67	$0.19+104.1%	-$4.61+23.3%	-$6.01	-$9.35	$0.05+102.7%	-$1.85	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	8M	8M+16.4%	7M+21.8%	5M	5M	41M+4.9%	39M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$7.2M+453.7%	$5.3M+285.7%	N/A	$925K-51.0%	$1.3M-66.4%	$1.4M-67.3%	N/A	$1.9M-45.2%
SG&A Expenses	$3.5M+66.4%	$11.4M+349.4%	N/A	$1.9M-22.6%	$2.1M-14.1%	$2.5M+1.0%	N/A	$2.5M-5.9%
Operating Income	-$10.6M-215.4%	-$16.7M-327.2%	N/A	-$2.8M+34.9%	-$3.4M+46.3%	-$3.9M+41.6%	N/A	-$4.4M+28.2%
EBITDA	N/A	N/A	N/A	-$2.8M+34.9%	-$3.4M+46.3%	-$3.9M+41.6%	N/A	-$4.4M+28.2%
Net Income	$17.5M+636.0%	-$125.4M-3241.5%	N/A	-$2.7M-112.2%	-$3.3M+60.4%	-$3.8M+56.2%	N/A	$22.5M+387.9%
EPS (Basic)	$0.36+183.7%	-$2.86-472.0%	-$33.38-5860.7%	-$0.36-112.1%	-$0.43+60.6%	-$0.50+55.8%	-$0.56+53.3%	$2.97+388.3%
EPS (Diluted)	-$0.14	-$2.86	-$33.38	-$0.36-112.1%	-$0.43+60.6%	-$0.50+55.8%	-$0.56+53.3%	$2.97+388.3%
Diluted Shares (Avg)	79M	44M	N/A	8M0.0%	8M0.0%	8M0.0%	N/A	8M0.0%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

NERV Balance Sheet

NERV quarterly balance sheet

Metric	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$98.0M+163.8%	$37.1M-34.7%	$56.9M+3.3%	$55.1M-28.6%	$77.1M+33.8%	$57.6M-25.6%	$77.5M-44.3%	$139.1M-24.3%	$183.7M+38.2%	$132.9M+61.0%	$82.6M+20.6%	$68.5M+134.6%	$29.2M
Current Assets	$83.1M+273.2%	$22.3M-47.0%	$42.0M+4.6%	$40.2M-35.4%	$62.2M+126.7%	$27.4M-41.8%	$47.1M-47.6%	$90.0M-30.5%	$129.5M+54.5%	$83.9M+150.5%	$33.5M+73.1%	$19.3M+963.0%	$1.8M
Cash & Equivalents	$82.3M+285.3%	$21.4M-47.8%	$40.9M+13.4%	$36.1M-40.6%	$60.8M+139.6%	$25.4M+18.4%	$21.4M-57.4%	$50.2M+92.8%	$26.1M-68.6%	$83.0M+480.9%	$14.3M-23.0%	$18.5M+919.9%	$1.8M
Short-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$24.4M-35.3%	$37.8M-63.0%	$102.1M	$0-100.0%	$17.9M	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$5.0M	$0	$0	$0	$0
Goodwill	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M+87.8%	$7.9M
Total Liabilities	$233.8M+272.0%	$62.8M-26.4%	$85.4M+13.6%	$75.1M+8.6%	$69.1M+1293.1%	$5.0M-90.0%	$49.7M+1.7%	$48.9M-6.2%	$52.1M+93.2%	$27.0M-1.1%	$27.3M+60.8%	$17.0M+88.4%	$9.0M
Current Liabilities	$2.3M-19.3%	$2.8M-15.1%	$3.3M+142.5%	$1.4M-51.1%	$2.8M-10.8%	$3.2M-52.3%	$6.6M+83.7%	$3.6M-47.2%	$6.8M-29.4%	$9.7M+82.1%	$5.3M+51.6%	$3.5M+149.5%	$1.4M
Non-Current Liabilities	$231.5M+285.8%	$60.0M-26.8%	$82.0M+11.2%	$73.7M+11.2%	$66.3M+3578.0%	$1.8M-95.8%	$43.1M-4.8%	$45.3M0.0%	$45.3M+162.0%	$17.3M-21.3%	$21.9M+63.2%	$13.4M+77.1%	$7.6M
Total Equity	-$140.7M-447.8%	-$25.7M+9.7%	-$28.5M-42.1%	-$20.0M-351.1%	$8.0M-84.9%	$52.7M+89.6%	$27.8M-69.2%	$90.3M-31.4%	$131.6M+24.2%	$106.0M+91.6%	$55.3M+7.4%	$51.5M+155.2%	$20.2M
Retained Earnings	-$688.8M-74.2%	-$395.4M+0.4%	-$396.8M-8.2%	-$366.8M-9.6%	-$334.7M-17.5%	-$284.8M+0.7%	-$286.7M-33.6%	-$214.6M-30.5%	-$164.4M-23.7%	-$132.9M-30.5%	-$101.8M-36.2%	-$74.7M-319.1%	-$17.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$95.1M+212.6%	$94.0M+186.7%	$98.0M+163.8%	$28.1M-34.4%	$30.4M-34.3%	$32.8M-35.1%	$37.1M-34.7%	$42.8M-32.2%
Current Assets	$79.7M+412.8%	$79.1M+341.3%	$83.1M+273.2%	$13.0M-53.4%	$15.5M-50.5%	$17.9M-49.7%	$22.3M-47.0%	$27.9M-42.1%
Cash & Equivalents	$24.7M+61.7%	$32.7M+88.9%	$82.3M+285.3%	$12.3M-53.7%	$15.2M-50.6%	$17.3M-50.3%	$21.4M-47.8%	$26.5M-43.4%
Short-Term Investments	$50.6M	$45.4M	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%	$14.9M0.0%
Total Liabilities	$296.6M+374.4%	$343.1M+453.8%	$233.8M+272.0%	$62.7M-2.8%	$62.5M-31.1%	$61.9M-28.9%	$62.8M-26.4%	$64.5M-22.5%
Current Liabilities	$4.0M+56.5%	$4.5M+130.2%	$2.3M-19.3%	$2.7M-40.4%	$2.5M-39.8%	$1.9M-31.2%	$2.8M-15.1%	$4.5M+33.8%
Non-Current Liabilities	$292.7M+387.8%	$338.6M+464.3%	$231.5M+285.8%	$60.0M0.0%	$60.0M-30.7%	$60.0M-28.8%	$60.0M-26.8%	$60.0M-24.8%
Total Equity	-$213.3M-564.3%	-$254.0M-771.4%	-$140.7M-447.8%	-$34.6M-59.6%	-$32.1M+27.8%	-$29.1M+20.3%	-$25.7M+9.7%	-$21.7M-8.1%
Retained Earnings	-$796.7M-98.0%	-$814.2M-104.0%	-$688.8M-74.2%	-$405.1M-3.6%	-$402.4M+2.7%	-$399.1M+1.5%	-$395.4M+0.4%	-$391.1M-0.9%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

NERV Cash Flow Statement

NERV quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$26.2M	-$13.5M+30.9%	-$19.6M-32.2%	-$14.8M+40.0%	-$24.6M-0.2%	-$24.6M+27.3%	-$33.8M+22.1%	-$43.4M-3.6%	-$41.9M-1456.1%	$3.1M+112.0%	-$25.7M-5.8%	-$24.3M+32.5%	-$36.0M-1564.7%	-$2.2M
Depreciation & Amortization	N/A	$5K0.0%	$5K0.0%	$5K	N/A	N/A	$16K-8.3%	$17K0.0%	$17K+57.4%	$11K-32.9%	$17K-4.3%	$17K-49.0%	$34K	N/A
Stock-Based Compensation	N/A	$1.3M+0.1%	$1.3M-32.7%	$2.0M-52.1%	$4.1M-21.3%	$5.2M-46.2%	$9.7M+5.8%	$9.2M+12.1%	$8.2M+62.6%	$5.0M+40.9%	$3.6M+62.2%	$2.2M-87.7%	$18.0M+2640.0%	$656K
Capital Expenditures	N/A	N/A	N/A	N/A	$16K	N/A	N/A	N/A	N/A	$52K	N/A	N/A	$46K+1311.2%	$3K
Free Cash Flow	N/A	N/A	N/A	N/A	-$24.7M	N/A	N/A	N/A	N/A	$3.0M	N/A	N/A	-$36.0M-1564.3%	-$2.2M
Investing Cash Flow	-$50.1M	$0	$0	$0+100.0%	-$16K	N/A	$24.5M+74.1%	$14.1M-79.7%	$69.5M+164.8%	-$107.2M	N/A	N/A	N/A	N/A
Financing Cash Flow	$85.7M	$74.5M	N/A	$19.6M+392074120.0%	-$5-100.0%	$60.0M+353.2%	$13.2M+2421.5%	$525K+115.7%	-$3.3M-107.1%	$47.2M	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$389	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$13.3M-553.5%	-$5.4M-33.3%	-$4.5M+13.3%	-$2.9M+33.0%	-$2.0M+48.1%	-$4.1M+33.2%	-$5.2M+13.8%	-$4.4M+9.4%
Depreciation & Amortization	N/A	N/A	$1K0.0%	$1K0.0%	$1K-0.1%	$1K+0.1%	$1K-0.1%	$1K+0.1%
Stock-Based Compensation	$2.3M+662.1%	$8.7M+2830.5%	N/A	$273K-11.3%	$298K-9.4%	$297K-32.3%	N/A	$308K-17.3%
Investing Cash Flow	-$4.8M	-$45.3M	$0	$0	$0	$0	$0	$0
Financing Cash Flow	$10.2M	$1.1M	$74.5M	-$45K	$0	$0	N/A	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

NERV Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NERV quarterly financial ratios

Metric	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	4.5%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	4.7%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	-625.7%-629.4pp	3.7%+263.5pp	-259.8%-204.3pp	-55.6%-31.6pp	-23.9%+5.3pp	-29.3%+19.7pp	-48.9%+61.5pp	-110.5%-94.3pp	-16.2%
Return on Assets	-299.5%-303.4pp	3.9%+56.6pp	-52.7%+5.6pp	-58.3%+6.4pp	-64.7%-68.1pp	3.4%+96.5pp	-93.1%-57.1pp	-36.1%-18.9pp	-17.2%+6.2pp	-23.4%+9.4pp	-32.8%+50.3pp	-83.1%-72.0pp	-11.2%
Current Ratio	36.28+28.4x	7.85-4.7x	12.57-16.6x	29.15+7.1x	22.07+13.4x	8.68+1.6x	7.11-17.8x	24.94+6.0x	18.94+10.3x	8.66+2.4x	6.29+0.8x	5.51+4.2x	1.29
Debt-to-Equity	N/A	N/A	N/A	N/A	8.67+8.6x	0.09-1.7x	1.79+1.2x	0.54+0.1x	0.40+0.1x	0.25-0.2x	0.49+0.2x	0.33-0.1x	0.45
Asset Turnover	N/A	0.000.0x	0.000.0x	0.000.0x	0.00-0.7x	0.71+0.7x	0.000.0x	0.000.0x	0.00	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Assets	18.4%+29.1pp	-133.4%-121.9pp	N/A	-9.8%-62.4pp	-10.7%+7.1pp	-11.4%+5.5pp	N/A	52.6%+65.0pp
Current Ratio	20.14+14.0x	17.65+8.4x	36.28+28.4x	4.87-1.4x	6.15-1.3x	9.21-3.4x	7.85-4.7x	6.23-8.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$140.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Minerva Neurosciences, Inc NERV	FY2025	N/A	-$293.4M	N/A	$151.8M	—
BioVie, Inc. BIVI	FY2026	N/A	-$22.1M	N/A	$11.1M	—
Lipocine Inc. LPCN	FY2025	$2.0M	-$9.6M	N/A	$15.9M	53/100
NextCure, Inc. NXTC	FY2025	N/A	-$55.8M	N/A	$31.0M	—
MetaVia Inc. MTVA	FY2025	N/A	-$13.0M	N/A	$8.8M	—
Portage Biotech Inc. PRTG	FY2018	N/A	$123.7M	N/A	$15.5M	—

Where Minerva Neurosciences, Inc Ranks

Frequently Asked Questions

Is Minerva Neurosciences, Inc profitable?

No, Minerva Neurosciences, Inc (NERV) reported a net income of -$293.4M in fiscal year 2025.

What is Minerva Neurosciences, Inc's EBITDA?

Minerva Neurosciences, Inc (NERV) had EBITDA of -$15.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Minerva Neurosciences, Inc's operating cash flow?

Minerva Neurosciences, Inc (NERV) recorded an outflow of $13.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Minerva Neurosciences, Inc's total assets?

Minerva Neurosciences, Inc (NERV) had $98.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Minerva Neurosciences, Inc spend on research and development?

Minerva Neurosciences, Inc (NERV) invested $5.8M in research and development during fiscal year 2025.

How many shares does Minerva Neurosciences, Inc have outstanding?

Minerva Neurosciences, Inc (NERV) had 43M shares outstanding as of fiscal year 2025.

What is Minerva Neurosciences, Inc's current ratio?

Minerva Neurosciences, Inc (NERV) had a current ratio of 36.28 as of fiscal year 2025, which is generally considered healthy.

What is Minerva Neurosciences, Inc's return on assets (ROA)?

Minerva Neurosciences, Inc (NERV) had a return on assets of -299.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Minerva Neurosciences, Inc's P/E ratio?

Minerva Neurosciences, Inc (NERV) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $151.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Minerva Neurosciences, Inc's price-to-sales ratio?

Minerva Neurosciences, Inc (NERV) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $151.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Minerva Neurosciences, Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Minerva Neurosciences, Inc (NERV) held $82.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $13.5M over that year. Dividing the one by the other, the reported balance equals about 73 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Minerva Neurosciences, Inc's debt-to-equity ratio negative or not reported?

Minerva Neurosciences, Inc (NERV) has negative shareholder equity of -$140.7M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Minerva Neurosciences, Inc's Piotroski F-Score?

Minerva Neurosciences, Inc (NERV) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Minerva Neurosciences, Inc's earnings high quality?

Minerva Neurosciences, Inc (NERV) reported a net loss of $293.4M while operations used $13.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.